Quick Facts
| Property | Value |
|---|---|
| Category | Growth Hormone Fragment Peptide |
| Risk Level | Low/Moderate |
| Administration | Subcutaneous Injection |
| Typical Frequency | Once Daily |
| Estimated Half-Life | Approximately 20–30 Minutes |
| Primary Research Interest | Fat Loss / Metabolic Support |
This material is provided strictly for educational and informational purposes related to peptide research and metabolic compounds. AOD-9604 is a biologically active peptide compound with potentially significant physiological effects. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.
1. Reconstitution Guide
- Vial Size: 10 mg
- Dilutant Type: BAC Water
- Amount of Dilutant Added: 3 mL
- Final Concentration: 3.33 mg/mL
At this concentration:
• 300 mcg = 0.090 mL (9.0 units)
• 500 mcg = 0.150 mL (15.0 units)
2. Route of Administration
AOD-9604 is most commonly administered as a subcutaneous injectable peptide compound.
- Primary Route: SubQ Injection
- Preferred Timing: Morning administration while fasted
- Administration Notes: Split-dose protocols including pre-cardio and pre-bedtime administration are also commonly discussed
3. Typical Research Protocols
- Product Strength: 3.33 mg/mL
- Typical Delivered Amount: 300–500 mcg daily
- Frequency: Once daily, preferably in the morning while fasted
- Cycle Length: 16 weeks on / 16 weeks off
- Special Notes: Unlike harsher compounds, AOD-9604 is often treated more like a slow-acting metabolic support peptide. Some users run it nearly continuously due to the relatively mild side effect profile. Doses can also be split throughout the day with pre-cardio and pre-bedtime dosing as popular variations.
4. Summary
AOD-9604 is a modified fragment of human growth hormone (HGH fragment 176-191) originally investigated for its potential fat-loss and metabolic effects without the broader anabolic or growth-promoting properties associated with full HGH administration.
Research interest in AOD-9604 primarily centers around adipose metabolism, lipolysis, and body composition support.
5. Mechanism of Action
AOD-9604 is believed to influence fat metabolism through pathways associated with lipolysis and inhibition of lipogenesis.
Unlike full-length HGH, the peptide was designed to isolate specific metabolic effects while minimizing broader endocrine stimulation.
Potential downstream effects discussed in research include:
- Increased fat mobilization
- Enhanced lipolysis
- Reduced fat storage signaling
- Metabolic support during calorie restriction
6. Potential Benefits
- Potential enhancement of fat metabolism
- Possible reductions in body fat percentage
- Non-stimulant metabolic support
- Potential compatibility with calorie-restricted diets
- Minimal direct anabolic activity compared to HGH
7. Potential Risks / Side Effects
Low/Moderate
- Injection site irritation
- Headaches
- Fatigue
- Nausea
- Water retention in some anecdotal reports
- Limited long-term human data
8. Half-Life
AOD-9604 has an estimated half-life commonly referenced in the range of approximately 20–30 minutes.
Despite its short circulating duration, downstream metabolic signaling effects may persist longer.
9. Storage Information
- Store refrigerated before and after reconstitution
- Protect from direct light exposure
- Avoid repeated freeze-thaw cycles
- Maintain sterile handling practices during preparation
10. Contraindications / Warnings
- Pregnancy or breastfeeding
- Uncontrolled endocrine disorders
- Severe metabolic instability
- Known hypersensitivity to peptide compounds
11. Research References
- PubMed
- NIH Publications
- Growth hormone fragment research literature
- Peer-reviewed metabolic research journals
CKF Tide Tables 